Stockscreener 앱 받기
186.29
3.94%
-7.65
시간 외 거래:
186.29
Resmed Inc 주식(RMD)의 최신 뉴스
ResMed Inc. stock falls Monday, underperforms market - MarketWatch
Do experts rate BHP, Cochlear, and ResMed shares as buys, holds, or sells? - MSN
Is ResMed stock underperforming the Dow? - MSN
Citigroup Adjusts Price Target on ResMed to $270 From $340, Maintains Buy Rating - marketscreener.com
ResMed Inc. (RMD) Stock Analysis: Exploring a Potential 38.93% Upside in the Healthcare Innovator - DirectorsTalk Interviews
ResMed (RMD) Stock Valuation Check After Mixed Returns And Undervaluation Signals - Yahoo Finance
Landscape Capital Management L.L.C. Sells 32,899 Shares of ResMed Inc. $RMD - MarketBeat
ResMed added as new short idea at Hedgeye - MSN
ResMed Inc. Stock (US7611521078): Ownership moves after year-to-date pressure - AD HOC NEWS
Should you continue to hold Resmed stock in your portfolio? - MSN
Milford Funds Ltd. Makes New $28.42 Million Investment in ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Why Are ResMed Shares Under Pressure Despite Solid Results? - Kalkine Media
Do Wall Street analysts like ResMed stock? - MSN
ResMed (RMD) Faces Potential 30% Decline Amid Market Concerns - GuruFocus
Is ResMed Inc. (RMD) A Good Stock To Buy Now? - Insider Monkey
Is ResMed Stock Underperforming the Dow? - Barchart.com
ResMed: GLP-1 Threats Are Overstated (NYSE:RMD) - Seeking Alpha
ResMed Inc. $RMD Shares Bought by Deutsche Bank AG - MarketBeat
ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
ResMed CEO Farrell Exercises Options and Sells Shares Under 10b5-1 Plan - TipRanks
Buy, hold, sell: Resmed, Goodman Group, Westpac shares - The Motley Fool Australia
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
ResMed chairman & CEO Michael Farrell sells $968k in stock By Investing.com - Investing.com Australia
ResMed chairman & CEO Michael Farrell sells $968k in stock - Investing.com Nigeria
ResMed Inc. stock (US7611521078): Sleep apnea specialist in focus after recent earnings update - AD HOC NEWS
ResMed (NYSE:RMD) CEO Sells $968,054.36 in Stock - MarketBeat
Resmed Insider Sold Shares Worth $968,064, According to a Recent SEC Filing - marketscreener.com
ResMed (NYSE: RMD) CEO sells 4,991 shares after option exercise - Stock Titan
Why ResMed Inc (RMD) Is Set to Outperform the Market: Insights i - GuruFocus
Is This the Right Time to Retain Resmed Stock in Your Portfolio? - Yahoo Finance
LGT Capital Partners LTD. Sells 25,752 Shares of ResMed Inc. $RMD - MarketBeat
BLI Banque de Luxembourg Investments Cuts Stake in ResMed Inc. $RMD - MarketBeat
ResMed (RMD) 10K Form and Latest SEC Filings 2026 - MarketBeat
Down 28% in a year, should I buy the dip on Resmed shares right now? - The Motley Fool Australia
ResMed stock (US7611521078): Revenue growth and sleep-apnea demand stay in focus - AD HOC NEWS
Michael Farrell sells 4,991 RMD shares (NYSE: RMD) via option exercise - Stock Titan
TD Asset Management Inc Has $20.63 Million Stake in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Sold by Los Angeles Capital Management LLC - MarketBeat
PBU The Pension Fund of Early Childhood & Youth Educators Makes New $7.93 Million Investment in ResMed Inc. $RMD - MarketBeat
Goldman Sachs Group Inc. Has $235.83 Million Stock Position in ResMed Inc. $RMD - MarketBeat
Cibc World Market Inc. Sells 8,768 Shares of ResMed Inc. $RMD - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Reduces Stock Position in ResMed Inc. $RMD - MarketBeat
ResMed (RMD) Valuation Check After Q3 FY2026 Results And Sleep Apnea Demand Update - Sahm
Prudential PLC Raises Position in ResMed Inc. $RMD - MarketBeat
Can ResMed's Sleep Apnea Growth Justify Current Valuation Views? - Kalkine Media
CIBC Asset Management Inc Boosts Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock ConferenceSlideshow - Seeking Alpha
ResMed (RMD) Acquires Noctrix Health to Expand Sleep Disorder Portfolio - Insider Monkey
ResMed Inc. $RMD Shares Sold by Marietta Investment Partners LLC - MarketBeat
ResMed (ASX:RMD) Analysis: What’s Driving Investor Sentiment? - Kalkine
Ord Minnett Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
A Look at ResMed Inc (RMD) After 4.2% Gain -- GF Value $271.26 v - GuruFocus
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
BofA Securities Maintains ResMed(RMD.US) With Buy Rating, Raises Target Price to $320 - Moomoo
ResMed completes $340m Noctrix Health acquisition - Yahoo Finance
1.81%
자본화:
|
볼륨(24시간):